retatrutide phase 2 trial type 2 diabetes Blood Sugar Results: 2.02% A1C Drop in Trials retatrutide phase 2 trial type

Research-use-only material imported under the correct customs classification and with proper labeling is a different regulatory category, but it is not a workaround for clinical supply and the research use only label does not shield downstream therapeutic use

This ensures faster absorption and quicker results, making injections an ideal option for those with severe deficiencies or absorption issues

doi: 10.2337/dc221710 119 ThomasMKNikooienejadABrayRCuiXWilsonJDuffinKet al

One study found that GH-releasing peptides led to significant reductions in visceral and subcutaneous fat , even without major diet changes

doi: 10.1111/bcpt.12878 105 PalakELebiedzinskaWAnisimowiczSSztachelskaMPierzynskiPWiczkowskiWet al

Data sources Orforglipron ATTAIN-1 trial: Eli Lilly press release (August 2025) Tirzepatide SURMOUNT-1 trial: Eli Lilly published data Indirect comparison metaanalysis: Circulation (2024) GI adverse events metaanalyses: Endocrinology, Diabetes & Metabolism (2024) and Diabetes, Obesity and Metabolism (2023)